NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal third quarter revenues grew 3 percent year over year, beating Wall Street expectations.

The company also increased its fiscal year revenue expectations by $14 million.

For the three months ended March 31, the firm reported total revenues of $196.9 million, compared to $190.5 million in Q3 2016, and topped the consensus Wall Street estimate of $189.1 million.